[1] Verma M. Epigenetic regulation of HIV, AIDS, and AIDS-related malignancies [J]. Methods Mol Biol, 2015, 1238 : 381-403.
[2] Ji Y, Lu H. Malignancies in HIV-Infected and AIDS Patients [J]. Adv Exp Med Biol, 2017, 1018 : 167-79.
[3] Sigel K, Dubrow R, Silverberg M, Crothers K, Braithwaite S, Justice A. Cancer screening in patients infected with HIV [J]. Current HIV/AIDS Reports, 2011, 8(3): 142-52.
[4] Novoa AM, de Olalla PG, Clos R, Orcau A, Rodríguez-Sanz M, Caylà JA. Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era [J]. Current HIV Research, 2008, 6(1): 77-81.
[5] Torre LA, Bray F, Siegel RL, Ferlay J, Tieulent JL, Jemal A. Global cancer statistics, 2012 [J]. CA: A Cancer Journal for Clinicians, 2015, 65(2): 87-108.
[6] Mitsuyasu RT. Non-AIDS-defining cancers [J]. Top Antivir Med, 2014, 22(3): 660-5.
[7] Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries [J]. European Journal of Cancer, 2001, 37(10): 1188-201.
[8] Deeken JF, Tjen-A-Looi A, Rudek MA, Okuliar C, Young M, Little RF, et al. The Rising Challenge of Non–AIDS-Defining Cancers in HIV-Infected Patients [J]. Clinical Infectious Diseases, 2012, 55(9): 1228-35.
[9] Wang CJ, Silverberg MJ, Abrams DI. Non-AIDS-Defining Malignancies in the HIV-Infected Population [J]. Curr Infect Dis Rep, 2014, 16(6): 406.
[10] Yang J, Su S, Zhao H, Wang D, Wang J, Zhang F, et al. Prevalence and mortality of cancer among HIV-infected inpatients in Beijing, China [J]. BMC Infect Dis, 2016, 16(1): 82.
[11] Nagata N, Nishijima T, Niikura R, Yokoyama T, Matsushita Y, Watanabe K, et al. Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study [J]. BMC Cancer, 2018, 18(1): 1066.
[12] Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection [J]. Nature Reviews Gastroenterology & Hepatology, 2013, 10(9): 553-62.
[13] Forner A, Llovet JM. Bruix J. Hepatocellular carcinoma [J]. The Lancet, 2012, 379(9822): 1245-55.
[14] Macdonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era [J]. World J Gastroenterol, 2008, 14(11): 1657-63.
[15] Lewin M, Gelu-Simeon M, Ostos M, Boufassa F, Sobesky R, Teicher E, et al. Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus [J]. Radiology, 2015, 277(2): 443-53.
[16] Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma [J]. World J Gastroenterol, 2015, 21(37): 10573-83.
[17] Dika IE, Harding JJ, Abou-Alfa GK. Hepatocellular carcinoma in patients with HIV [J]. Current Opinion in Hiv & Aids, 2017, 12(1): 20-5.
[18] Shiels MS, Cole SR, Kirk GD, Poole C. A Meta-Analysis of the Incidence of Non-AIDS Cancers in HIV-Infected Individuals [J]. Journal of Acquired Immune Deficiency Syndromes, 2009, 52(5): 611-22.
[19] Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The Effect of HIV Viral Control on the Incidence of Hepatocellular Carcinoma in Veterans With Hepatitis C and HIV Coinfection [J]. J Acquir Immune Defic Syndr, 2015, 68(4): 456-62.
[20] Choi JY, Lee JM, Sirlin CB. CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part I. Development, Growth, and Spread: Key Pathologic and Imaging Aspects [J]. Radiology, 2014, 272(3): 635-54.
[21] Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma [J]. Seminars in Liver Disease, 2005, 25(2): 181-200.
[22] Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study [J]. Journal of Hepatology, 2007, 47(4): 527-37.
[23] McKnight R, Nassar A, Cohen C, Siddiqui MT. Arginase‐1: A novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology [J]. Cancer Cytopathology, 2012, 120(4): 223-9.
[24] de Boer WB, Segal A, Frost FA, Sterrett GF. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies? [J]. Cancer, 2000, 90(5): 273-8.
[25] Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, et al. Detection of Hepatocellular Carcinoma with PET/CT: A Prospective Comparison of 18F-Fluorocholine and 18F-FDG in Patients with Cirrhosis or Chronic Liver Disease [J]. Journal of Nuclear Medicine, 2010, 51(11): 1699-706.
[26] Enan ET, El-Hawary AK, El-Tantawy DA, Abu-Hashim MM, Helal NM. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions [J]. Annals of Diagnostic Pathology, 2013, 17(6): 490-3.
[27] Cui DJ, Wu Y, Wen DH. CD34, PCNA and CK19 expressions in AFP- hepatocellular carcinoma. [J]. Eur Rev Med Pharmacol Sci, 2018, 22(16): 5200-5.
[28] Yao M, Wang L, Fang M, Zheng W, Dong Z, Yao D. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma [J]. Bioscience Trends, 2016, 10(5): 337-43.
[29] Montalbano M, Georgiadis J, Masterson AL, McGuire JT, Prajapati J, Shirafkan A, et al. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review) [J]. Oncology Reports, 2017, 37(3): 1291-300.
[30] Liu X, Wang SK, Zhang K, Zhang H, Pan Q, Liu Z, et al. Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers [J]. Carcinogenesis, 2015, 36(2): 232-42.
[31] Shi W, Hu J, Zhu S, Shen X, Zhang X, Yang C, et al. Expression of MTA2 and Ki-67 in hepatocellular carcinoma and their correlation with prognosis [J]. Int J Clin Exp Pathol, 2015, 8(10): 13083-9.
[32] Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma [J]. Cancer, 2005, 103(2): 307-12.
[33] Luo Y, Ren F, Liu Y, Shi Z, Tan Z, Xiong H, et al. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: A meta-analysis [J]. International Journal of Clinical & Experimental Medicine, 2015, 8(7): 10235-47.